Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications

Contributed by: Business Wire

Logo

Tags

Biotechnology

Pharmaceutical

Medical Supplies

Oncology

Health

Medical Devices

Genetics

Clinical Trials

Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy

More Like This

First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer

Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types

PR Newswire associated0

SOPHiA DDM™ Platform Certified Under IVDR

Saphetor SA receives IVDR Certification for clinical diagnosis support NGS data analysis platform, VarSome Clinical, ensuring enhanced safety and performance standards

Agendia Achieves CE-IVDR Certification for its MammaPrint® and BluePrint® Breast Cancer Assays

AliveDx receives IVDR Certification of its Manufacturing Sites in Switzerland and United Kingdom

EU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEA

ZeptoMetrix Awarded in Vitro Diagnostic Regulation (IVDR) Certification